Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Pacific Biosciences of California Inc Stock Research

PACB

8.94USD-0.06(-0.67%)Market Closed
Watchlist

Market Summary

USD8.94-0.06
Market Closed
-0.67%

PACB Alerts

  • 3 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Losses in recent quarter

PACB Stock Price

PACB RSI Chart

PACB Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-7.02

Price/Sales (Trailing)

15.32

EV/EBITDA

-6.9

Price/Free Cashflow

-8.14

PACB Price/Sales (Trailing)

PACB Profitability

Operating Margin

33.31%

EBT Margin

-248.07%

Return on Equity

-46.35%

Return on Assets

-16.91%

Free Cashflow Yield

-12.29%

PACB Fundamentals

PACB Revenue

Revenue (TTM)

146.1M

Revenue Y/Y

34.13%

Revenue Q/Q

22.3%

PACB Earnings

Earnings (TTM)

-319.2M

Earnings Y/Y

2.19%

Earnings Q/Q

20.66%

Price Action

52 Week Range

4.9714.55
(Low)(High)

Last 7 days

-14.2%

Last 30 days

-14.8%

Last 90 days

-28.5%

Trailing 12 Months

65.3%

PACB Financial Health

Current Ratio

3.69

PACB Investor Care

Shares Dilution (1Y)

11.57%

Diluted EPS (TTM)

-1.35

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for PACB

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-09-18
HENRY CHRISTIAN O
sold
-980,255
10.122
-96,844
see remarks
2023-09-11
HENRY CHRISTIAN O
sold
-104,520
10.452
-10,000
see remarks
2023-08-17
Eidel Jeff
sold
-274,844
10.597
-25,936
see remarks
2023-08-17
HENRY CHRISTIAN O
sold
-105,000
10.5
-10,000
see remarks
2023-08-16
Van Oene Mark
sold
-287,122
11.00
-26,102
see remarks
2023-05-18
Farmer Michele
sold
-65,027
12.59
-5,165
see remarks
2023-05-18
MOHR MARSHALL
acquired
63,500
2.54
25,000
-
2023-03-15
Ericson William W.
sold
-67,114
8.9
-7,541
-
2023-03-15
Ericson William W.
acquired
63,500
2.54
25,000
-
2023-03-03
Farmer Michele
sold
-29,931
9.493
-3,153
see remarks

1–10 of 50

Which funds bought or sold PACB recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-21
Jefferies Group LLC
reduced
-40.00
-46,850
174,150
-%
2023-09-20
BARCLAYS PLC
added
100
2,344,000
4,141,000
-%
2023-09-12
Farther Finance Advisors, LLC
reduced
-55.12
-10,953
11,651
-%
2023-09-06
Deep Track Capital, LP
reduced
-58.59
-21,279,900
19,301,000
0.89%
2023-08-22
VIRGINIA RETIREMENT SYSTEMS ET AL
added
101
212,940
375,060
-%
2023-08-21
OSAIC HOLDINGS, INC.
reduced
-2.75
56,966
539,739
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
4.21
640,297
3,892,640
-%
2023-08-16
Neo Ivy Capital Management
new
-
802,000
802,000
0.42%
2023-08-16
GTS SECURITIES LLC
new
-
2,763,730
2,763,730
0.09%
2023-08-16
Nuveen Asset Management, LLC
added
0.8
1,201,290
8,818,290
-%

1–10 of 43

Latest Funds Activity

Are funds buying PACB calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PACB
No. of Funds

Schedule 13G FIlings of Pacific Biosciences of California

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2023
capital international investors
2.7%
6,099,681
SC 13G/A
Feb 13, 2023
madrone capital partners, llc
7.3%
16,415,933
SC 13G/A
Feb 10, 2023
nikko asset management americas, inc.
6.26%
14,166,193
SC 13G/A
Feb 10, 2023
ark investment management llc
11.36%
25,691,681
SC 13G/A
Feb 10, 2023
jackson square partners, llc
6.64%
15,005,177
SC 13G/A
Feb 09, 2023
vanguard group inc
8.97%
20,279,035
SC 13G/A
Feb 03, 2023
blackrock inc.
8.2%
18,534,459
SC 13G/A
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
6.26%
14,166,193
SC 13G/A
Jun 01, 2022
madrone capital partners, llc
6.0%
13,415,933
SC 13G
Feb 14, 2022
nikko asset management americas, inc.
5.40%
11,915,025
SC 13G

Recent SEC filings of Pacific Biosciences of California

View All Filings
Date Filed Form Type Document
Sep 22, 2023
8-K/A
Current Report
Sep 19, 2023
4
Insider Trading
Sep 18, 2023
144
Notice of Insider Sale Intent
Sep 12, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
4
Insider Trading
Aug 18, 2023
144/A
144/A
Aug 17, 2023
D
D
Aug 17, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Pacific Biosciences of California)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
32.6B
7.0B
-6.48% -10.43%
28.81
4.67
5.03% -14.68%
24.1B
4.0B
-5.58% -3.13%
27.06
6.08
2.30% 16.37%
20.9B
4.5B
-19.21% -31.55%
-5
4.69
-4.92% -21931.58%
16.1B
2.8B
-15.95% -22.45%
19.74
5.69
-24.31% 21.35%
15.9B
3.0B
-0.75% -2.22%
23.55
5.31
3.16% -3.93%
MID-CAP
SMALL-CAP
2.2B
146.1M
-14.78% 65.25%
-7.02
15.32
4.72% -55.19%
939.5M
112.0M
0.16% 189.80%
-14.28
8.39
0.83% 16.42%
733.4M
189.6M
-22.00% -26.52%
-3.84
3.87
18.74% 17.75%
174.6M
114.1M
-3.08% 57.31%
-32.16
1.53
-5.49% -48.58%
108.9M
99.2M
-12.85% -74.80%
-1.92
1.1
-26.56% -199.52%
97.1M
31.5M
-3.63% 53.68%
-0.66
3.08
35.12% -38.47%
72.8M
52.7M
-15.89% -34.39%
-9.64
1.38
2.10% -1984.29%
71.3M
143.9M
-47.74% -88.57%
-0.43
0.5
0.71% -18.99%
60.1M
67.1M
-27.06% -59.74%
-0.55
0.9
-12.13% -17.68%

Pacific Biosciences of California News

Nasdaq
RSI Alert: Pacific Biosciences of California (PACB) Now Oversold.
Nasdaq,
31 hours ago
Marketscreener.com
The Motley Fool

Returns for PACB

Cumulative Returns on PACB

10.0%


10-Year Cumulative Returns

-0.3%


7-Year Cumulative Returns

13.2%


5-Year Cumulative Returns

0.6%


3-Year Cumulative Returns

Risks for PACB

What is the probability of a big loss on PACB?

100%


Probability that Pacific Biosciences of California stock will be more than 20% underwater in next one year

87.7%


Probability that Pacific Biosciences of California stock will be more than 30% underwater in next one year.

69.6%


Probability that Pacific Biosciences of California stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does PACB drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Pacific Biosciences of California was unfortunately bought at previous high price.

Drawdowns

Financials for Pacific Biosciences of California

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue9.0%146,137,000134,031,000128,304,000136,970,000139,546,000134,689,000130,513,000121,630,000105,825,00092,292,00078,893,00079,687,00082,520,00090,064,00090,891,00082,487,00078,732,00075,689,00078,626,00084,035,00089,420,000
Cost Of Revenue14.3%102,143,00089,390,00079,269,00076,309,00077,068,00074,651,00071,653,00069,866,66765,754,00064,080,00046,327,000---56,315,000------
Gross Profit-1.4%43,994,00044,641,00049,035,00060,661,00062,478,00060,038,00058,860,00053,495,00045,195,00038,055,00032,566,00034,097,00033,947,00036,947,00034,576,00027,390,00023,668,00022,917,00025,096,00028,844,00033,879,000
Operating Expenses1.2%370,125,000365,566,000356,231,000345,449,000347,122,000314,286,000269,295,000223,231,000164,630,000143,441,000136,951,000132,422,000136,211,000140,067,000135,121,000140,641,000133,475,000130,089,000126,083,000119,737,000121,671,000
  S&GA Expenses0.8%162,189,000160,868,000160,854,000153,171,000147,982,000137,790,000124,124,000104,758,00087,924,00073,991,00072,799,00071,422,00076,716,00080,672,00075,491,00079,021,00072,461,00068,321,00063,489,00057,780,00058,226,000
  R&D Expenses-2.2%184,827,000189,002,000193,000,000192,953,000173,369,000145,287,000112,899,00087,747,00076,706,00069,450,00064,152,00061,000,00059,495,00059,395,00059,630,00061,620,00061,014,00061,768,00062,594,00061,957,00063,445,000
EBITDA100.0%--307,903,333-290,078,000-266,535,000--252,572,000-255,142,0008,873,000-38,407,00036,885,000-86,672,000-75,310,000-74,666,000-74,308,000------
EBITDA Margin100.0%--2.30-2.26-1.95--1.88-1.950.07-0.420.47-1.09-0.91-0.83-0.82------
Interest Expenses-0.9%14,496,00014,623,00014,690,00014,521,00014,530,00014,438,00012,530,0009,051,0005,378,0001,789,000267,000945,0001,609,0002,253,0002,611,0002,561,0002,513,0002,467,0002,423,0002,419,0002,436,000
Earnings Before Taxes0.5%-319,203,000-320,764,000-314,248,000-298,018,000-299,329,000-303,913,333-274,872,000-6,694,000--29,403,000-94,832,000---84,134,000------
EBT Margin100.0%--2.48-2.45-2.12--2.04-2.11-0.06-0.320.37-1.19-1.02-0.93-0.93------
Net Income0.5%-319,203,000-320,764,000-314,248,000-299,193,000-205,680,000-175,287,000-181,223,000-36,959,000-77,209,000-59,294,00029,403,000-45,623,000-51,038,000-52,548,000-84,134,000-114,842,000-110,763,000-108,707,000-102,562,000-92,525,000-89,502,000
Net Income Margin100.0%--2.39-2.45-2.18-1.47-1.30-1.39-0.30-0.73-0.640.37-0.57-0.62-0.58-0.93------
Free Cashflow100.0%--295,706,000-279,961,000-249,041,000-223,574,000-176,273,000-117,111,000-96,891,000-73,460,000-80,287,00018,464,00014,473,00014,728,00020,664,000-81,148,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-2.6%1,8481,8961,7671,8191,8761,9372,0072,0341,2461,253414300214235148146171186170183137
  Current Assets-4.6%9369818529149701,0291,1011,1301,1891,19635624015117081.0077.0099.0011313214496.00
    Cash Equivalents-40.9%20935432530431042946642546093282.0069.0043.0069.0034.0033.0030.0038.0034.0038.0023.00
  Inventory9.1%68.0062.0050.0043.0036.0030.0025.0018.0018.0016.0014.0016.0017.0016.0013.0015.0017.0020.0018.0020.0023.00
  Net PPE-1.3%40.0041.0042.0039.0038.0036.0033.0031.0025.0024.0025.0027.0028.0029.0030.0032.0033.0034.0034.0034.0036.00
  Goodwill0%410410410410410410410391-------------
Liabilities0.1%1,2061,2041,2041,1921,1941,2021,2161,19398897278.0017117217493.0095.0095.0091.0056.0051.0052.00
  Current Liabilities2.2%27126626382.0084.0061.0072.0056.0045.0034.0039.0013013113249.0051.0049.0045.0027.0022.0022.00
Shareholder's Equity-7.2%64269256362768273579184125828133512941.0060.0055.0051.0076.0095.0011413285.00
  Retained Earnings-4.3%-1,690-1,620-1,532-1,447-1,370-1,299-1,218-1,148-1,165-1,124-1,036-1,111-1,088-1,065-1,066-1,066-1,037-1,012-982-951-926
  Additional Paid-In Capital0.9%2,3352,3142,1002,0812,0582,0382,0101,9891,4231,4051,3721,2411,1291,1251,1211,1171,1131,1071,0961,0831,012
Shares Outstanding0.3%250250227226224222221202199195192167154153153153153151150149132
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations6.7%-260-278-263-234-211-167-111-93.73-70.89-78.9620.0016.0016.0022.00-78.31-79.12-76.03-72.97-66.43-67.64-71.31
  Share Based Compensation-1.5%73.0074.0079.0080.0089.0086.0073.0060.0036.0024.0018.0016.0015.0016.0016.0020.0021.0022.0023.0021.0021.00
Cashflow From Investing-2593.8%-36.831.00116101-244-644-678-842-614-156-219-124-40.93-30.2662.0060.003.007.00-38.41-22.2220.00
Cashflow From Financing-2.6%19520010.0010.003073091,1701,2941,1021,09925214437.0038.0027.0014.0080.0078.0010710238.00

PACB Income Statement

2023-06-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 47,573$ 35,467$ 86,473$ 68,640
Cost of Revenue:    
Amortization of intangible assets183183366366
Total cost of revenue32,02719,27461,16638,292
Gross profit15,54616,19325,30730,348
Operating Expense:    
Research and development46,17350,34895,112103,285
Sales, general and administrative40,57339,25280,39179,056
Change in fair value of contingent consideration1,975(5,438)14,231(6,501)
Total operating expense88,72184,162189,734175,840
Operating loss(73,175)(67,969)(164,427)(145,492)
Loss on extinguishment of debt(2,033)0(2,033)0
Interest expense(3,554)(3,681)(7,184)(7,378)
Other income (expense), net8,92925615,796(23)
Loss before expense (benefit) from income taxes(69,833)(71,394)(157,848)(152,893)
Expense (benefit) from income taxes0000
Net loss(69,833)(71,394)(157,848)(152,893)
Other comprehensive (loss) income:    
Unrealized (loss) gain on investments(762)(1,372)2,079(4,370)
Comprehensive loss$ (70,595)$ (72,766)$ (155,769)$ (157,263)
Net loss per share:    
Basic (in dollars per share)$ (0.28)$ (0.32)$ (0.64)$ (0.68)
Diluted (in dollars per share)$ (0.28)$ (0.32)$ (0.64)$ (0.68)
Weighted average shares outstanding used in calculating net loss per share:    
Basic (in shares)250,070224,499246,074223,400
Diluted (in shares)250,070224,499246,074223,400
Product revenue    
Revenue:    
Total revenue$ 43,655$ 30,175$ 78,309$ 58,419
Cost of Revenue:    
Cost of revenue28,43215,49953,59630,319
Service and other revenue    
Revenue:    
Total revenue3,9185,2928,16410,221
Cost of Revenue:    
Cost of revenue$ 3,412$ 3,592$ 7,204$ 7,607

PACB Balance Sheet

2023-06-30
Condensed Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets  
Cash and cash equivalents$ 209,287$ 325,089
Investments620,575447,229
Accounts receivable, net24,03418,786
Inventory, net67,60850,381
Prepaid expenses and other current assets13,74810,289
Short-term restricted cash300300
Total current assets935,552852,074
Property and equipment, net40,31741,580
Operating lease right-of-use assets, net36,44439,763
Long-term restricted cash2,4222,922
Intangible assets, net409,779410,245
Goodwill409,974409,974
Other long-term assets13,14310,528
Total assets1,847,6311,767,086
Current liabilities  
Accounts payable16,51212,028
Accrued expenses27,01032,596
Deferred revenue, current24,98330,498
Operating lease liabilities, current9,2438,886
Other liabilities, current7,3367,233
Contingent consideration liability, current186,325172,094
Total current liabilities271,409263,335
Deferred revenue, non-current4,9921,794
Operating lease liabilities, non-current36,59941,070
Convertible senior notes, net, non-current891,795896,683
Other liabilities, non-current8371,300
Total liabilities1,205,6321,204,182
Commitments and contingencies
Stockholders’ equity  
Authorized 50,000 shares; No shares issued or outstanding00
Authorized 1,000,000 shares; issued and outstanding 250,473 and 226,505 shares at June 30, 2023 and December 31, 2022, respectively250227
Additional paid-in capital2,334,6232,099,782
Accumulated other comprehensive loss(2,686)(4,765)
Accumulated deficit(1,690,188)(1,532,340)
Total stockholders’ equity641,999562,904
Total liabilities and stockholders’ equity$ 1,847,631$ 1,767,086
Christian O. Henry
730
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.